Treatment of Atopic dermatitis in children by using Kukkiladhi chooranam and Milagu ennai

Phase 2

Not yet recruiting

• Conditions: Atopic dermatitis, unspecified,

• Registration Number: CTRI/2025/04/084915
• Lead Sponsor: National Institute of Siddha

Brief Summary

**Introduction:**

As per the Siddha literature, Karappan is associated with the symptoms of erythema, oedema, intense pruritis, exudation, crusting and scaling. In the textbook of Kuzhandhai Maruthuvam (Balavagadam), the signs and symptoms of Karappan described are nearly correlated with the signs and symptoms of Atopic dermatitis. Atopic dermatitis (AD) or Eczema, is mainly a disease of childhood. Childhood- onset AD begins early in life, with 50% diagnosed in the first year of life and 85% by 5 years of age. In the textbook of Udal thathuvam the humoral changes of Karappan is quoted as “Iruthirogam karappan viranathodam”. From this it is clear Kabam humor is increased in this disease. Taste such as karppu (pungent), kaippu (bitter), thuvarppu (astringent) are said to balance the kabam humor. Most of the ingredients in Kukkiladhi chooranam and Milagu ennai have karppu (pungent), kaippu (bitter) taste which help in decreasing the kaba humor.



**Materials and methods:**

An open Clinical trial will be conducted in Kuzhandhai Maruthuvam OPD of Ayothidoss Pandithar hospital, National Institute of Siddha, Tambaram Sanatorium,Chennai-600047. A total of 30 children (male and female) aged 3 to 12 years of age diagnosed with Atopic dermatitis (Karappan) and who are willing to participate in the trial by signing consent form and assent form will be enrolled based on inclusion and exclusion criteria. Kukkiladhi  chooranam (Internal medicine) and Milagu ennai (External medicine) will be given for a duration of 48 days.



**Results:**

Effectiveness of the trial drug will be measured by using EASI Score before and after treatment.



**Keywords:**

karappan, Atopic dermatitis, Kukkiladhi chooranam, Milagu ennai

Detailed Description

Not available

Study Timeline

• Study Start: 2025-05-30
• Last Update Posted: 2025-06-04

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Children of both sex in the age group of 3 to 12 years with symptoms according to EASI Score: 1.Erythema 2.Oedema 3.Oozing 4.Itching 5.Crusting 6.Scaling 7.Lichenified plaques.

Exclusion Criteria

1.K/C/O Scabies 2.K/C/O Contact dermatitis 3.K/C/O Seborrheic Dermatitis 4.K/C/O Psoriasis 5.K/C/O Secondary Bacterial Infections 6.K/C/O Furunculosis 7.K/C/O Neurodermatitis 8.Any other serious illness.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Effectiveness of the trial drug will be measured by using EASI score before and after treatment	48 days

Secondary Outcome Measures

Name	Time	Method
1.The characteristics of the trial drug Kukkiladhi chooranam will be analysed as per PLIM guidelines	2.The characteristics of the trial drug Milagu ennai will be analysed as per PLIM guidelines

Trial Locations

Locations (1)

National Institute of Siddha; 🇮🇳 Kancheepuram, TAMIL NADU, India

National Institute of Siddha

🇮🇳Kancheepuram, TAMIL NADU, India

Dr J Reena

Principal investigator

9944381097

reenajayaraman@gmail.com